Oppenheimer Maintains Outperform on MediWound, Lowers Price Target to $30
Oppenheimer analyst Jeff Jones maintains MediWound (NASDAQ:MDWD) with a Outperform and lowers the price target from $32 to $30.
Read original at benzingaStocks · News reference
MediWound Q2 2026 Earnings Call: Complete Transcript
MediWound (NASDAQ:MDWD) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts and financial
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 13, 2026, 1:43 PM
- Checked
- Aug 13, 2026, 1:43 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
MediWound Q2 EPS $(0.77) Misses $(0.76) Estimate, Sales $3.092M Beat $2.588M Estimate
MediWound (NASDAQ:MDWD) reported quarterly losses of $(0.77) per share which missed the analyst consensus estimate of $(0.76) by 1.32 percent. This is a 37.4 percent increase over losses of $(1.23) per share from the
Read original at benzingaMediWound Affirms FY2026 Sales Guidance of $24.000M-$26.000M vs $24.125M Est
MediWound (NASDAQ:MDWD) affirms FY2026 sales outlook from $24.000 million-$26.000 million to $24.000 million-$26.000 million vs $24.125 million estimate.
Read original at benzinga